uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

uniQure N.V.NASDAQ: QURE

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$8.78M, compared with -$3.81M a year earlier. Trailing-twelve-month other income / expenses was -$11.92M.

Context

  • Other income / expenses amounted to 34.2% of revenue in FY2025, down 160.6 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$8.78M or moves back toward the trailing-twelve-month quarterly average of -$2.98M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.78M-178.7% QoQ
Last fiscal yearDec 2025
-$5.51M+89.6% YoY
LTMMar 2026
-$11.92M+74.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-130.4%——
1 year+89.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(5.51M) USD
Year-over-year change
+89.6%

Other Income / Expenses vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 other income / expenses of -$11.92M is the 5th highest of the 8 companies compared; the peer median is $6.49M.
  • Its year-over-year change of +74.0% is the highest of 8, against a peer median of -38.7%.
  • Other income / expenses amounts to 65.9% of revenue for QURE, versus a peer median of 21.1%.
QURE Competitors Peer median
Other Income / Expenses for QURE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$18.65M -30.6%+97.1%21.1%
NGNENeurogene Inc.LTM Mar 2026$12.12M +36.6%+113.1%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$10.91M -38.7%+40.3%29.9%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$6.49M -46.8%+29.6%—
QUREuniQure N.V.LTM Mar 2026-$11.92M +74.0%—65.9%
MGTXMeiraGTx Holdings plcLTM Mar 2026-$15.34M -85.0%—19.2%
RGNXREGENXBIO Inc.LTM Mar 2026-$33.33M -9907.5%—37.9%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$43.77M -30.4%—6.5%
Peer median (excluding QURE) $6.49M-38.7%+68.7%21.1%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue524M106.48M15.84M27.12M16.1M
Cost of Revenue24.98M3.34M13.63M18.33M1.69M
Gross Profit499.03M103.14M2.22M8.79M14.41M
Gross Margin95.2%96.9%14.0%32.4%89.5%
Research & Development143.55M197.59M214.86M143.78M140.67M
Selling, General & Admin56.29M54.7M73.08M50.68M65.34M
Operating Expenses188.41M246.3M285.09M193.09M202.24M
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
EBITDA319M(108.02M)(253.1M)(160.75M)(116.59M)
EBITDA Margin60.9%-101.4%-1597.6%-592.7%-724.2%
Operating Income310.62M(143.16M)(282.87M)(184.29M)(187.83M)
Operating Margin59.3%-134.4%-1785.5%-679.6%-1166.8%
Interest Income162K609K19.56M21.42M16.97M
Interest Expense7.47M11.7M41.56M63.74M61.99M
Other Income / Expenses22.19M14.9M(23.69M)(52.83M)(5.51M)
Income Before Tax332.81M(128.26M)(306.56M)(237.13M)(193.34M)
Pre-Tax Margin63.5%-120.5%-1935.0%-874.4%-1201.0%
Income Tax Expense3.22M(1.47M)1.92M2.43M5.63M
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Net Margin62.9%-119.1%-1947.1%-883.4%-1236.0%
EPS (Basic)7.17(2.71)(6.47)(4.92)(3.46)
EPS (Diluted)7.04(2.71)(6.47)(4.92)(3.46)
Weighted Avg Shares45.99M46.74M47.67M48.65M57.5M
Weighted Avg Shares (Diluted)46.84M46.74M47.67M48.65M57.5M

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.